X4 Pharma Rg
X4 Pharmaceuticals, Inc., a Boston‑based biopharma developing oral CXCR4 antagonists for rare immune disorders. Its lead asset, XOLREMDI, is in Phase 3 trials, with mavorixafor candidates in oncology and hematology, backed by Abbisko and Norgine licenses.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 143
- HQ: Boston
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.